title: IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab.
abstract: Although biological drugs in psoriasis treatment show clinical efficacy, there are still a proportion of patients in whom little treatment response is obtained. The aim of this study was to identify molecular biomarkers for treatment response and to investigate the molecular effects of ustekinumab treatment of psoriasis. The mRNA expression of various genes in skin biopsies was analysed by quantitative polymerase chain reaction (qPCR). At baseline, there was no significant clinical difference be-tween responders and non-responders. Ten patients were clinical responders, with a mean baseline Psoriasis Area and Severity Index (PASI) score of 15.4 and a mean percentage improvement of 89.6%. No significant reduction in PASI during treatment was seen among the 5 non-responders. In the responder group, ustekinumab therapy reduced the mRNA expression of the majority of the studied genes in lesional psoriatic skin. IL-20, IL-21 and p40 mRNA expression in lesional psoriatic skin at baseline were significantly upregulated by factors of 2.7, 2.4 and 2.3, respectively, among non-responders compared with responders. The mRNA levels of p40, IL-20 and IL-21 at baseline may serve as potential predictors of treatment response to ustekinumab treatment.
authors.affiliation: Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
authors.forename: Anne
authors.initials: A
authors.lastname: Gedebjerg
authors.forename: Claus
authors.initials: C
authors.lastname: Johansen
authors.forename: Knud
authors.initials: K
authors.lastname: Kragballe
authors.forename: Lars
authors.initials: L
authors.lastname: Iversen
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D001706:Biopsy; D005819:Genetic Markers; D005838:Genotype; D006801:Humans; D053762:Interleukin-12 Subunit p40 / Q000235:genetics*; D007378:Interleukins / Q000235:genetics*; D010641:Phenotype; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012720:Severity of Illness Index; D012867:Skin / Q000276:immunology* / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation; D000069549:Ustekinumab; D000098546:Interleukin-21
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D005819:Genetic Markers; C500879:IL12B protein, human; D053762:Interleukin-12 Subunit p40; D007378:Interleukins; D012333:RNA, Messenger; D000069549:Ustekinumab; D000098546:Interleukin-21; C422042:interleukin 20